Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Watson reacquires North American marketing rights to Androderm

June 7, 1999

Alteon completes phase I human trials of ALT-711

June 7, 1999

Benzenes with hypoglycemic and hypolipidemic effects in the Ono pipeline

June 4, 1999

Hematopoietic agents in development at Toray

June 4, 1999

LY-333531 reduces leukocyte accumulation in retinal microcirculation of diabetic rats

June 4, 1999

Preclinical study indicates potential of OGT-918 in treating complicated metabolic disorders

June 3, 1999

Ketone-based hematopoietic agents developed at Toray

June 3, 1999

Licensing opportunity from Cornell Research Foundation: antidiabetic fagopyritols

June 3, 1999

Plant-based Novogen product increases HDL cholesterol

June 3, 1999

Squalene synthase inhibitor BMS-184494 tested in humans; spotlight on squalene synthase inhibitors

June 3, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...